Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Abstract Text:

David A Rizzieri,Liang Piu Koh,Gwynn D Long,Cristina Gasparetto,Keith M Sullivan,Mitchell Horwitz,John Chute,Clayton Smith,Jerald Z Gong,Anand Lagoo,Donna Niedzwiecki,Jeannette M Dowell,Barbara Waters-Pick,CongXiao Liu,Dawn Marshall,James J Vredenburgh,Jon Gockerman,Carlos Decastro,Joseph Moore,Nelson J Chao,

PURPOSE: Allogeneic transplantation is typically limited to younger patients having a matched donor. To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related donor with one fully mismatched HLA haplotype. PATIENTS AND METHODS: Fludarabine, cyclophosphamide, and alemtuzumab were used as the preparatory regimen. Additional graft-versus-host disease (GVHD) prophylaxis included mycophenolate with or without cyclosporine. Patients with persistence of disease had a donor lymphocyte boost planned. Toxicities, engraftment, response, survival, and immune recovery are reported. RESULTS: Forty-nine patients with hematologic malignancies or marrow failure and no other available donors were enrolled. Ninety-four percent of patients had successful engraftment, and 8% had secondary graft failure. The treatment-related mortality rate was 10.2%, and 8% of patients had severe GVHD. Encouraging evidence of quantitative lymphocyte recovery through expansion of transplanted T cells was noted by 3 to 6 months. Seventy-five percent of patients attained a complete remission, and 1-year survival rate was 31% (95% CI, 18% to 44%). A standard-risk group of 19 patients with aplasia or in remission at transplantation demonstrated a 63% 1-year survival rate (95% CI, 38% to 80%) and 2.9-year median overall survival time (95% CI, 6.2 to 48 months). CONCLUSION: Nonmyeloablative therapy using haploidentical family member donors is feasible because the main obstacles of GVHD and graft rejection are manageable, allowing readily available stem-cell donors to be found for nearly all patients. Further qualitative and quantitative improvement in immune recovery is needed to address the high rate of relapse and risk of severe infections.

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Publishing Authors By Initials

DA Rizzieri,LP Koh,GD Long,C Gasparetto,KM Sullivan,M Horwitz,J Chute,C Smith,JZ Gong,A Lagoo,D Niedzwiecki,JM Dowell,B Waters-Pick,C Liu,D Marshall,JJ Vredenburgh,J Gockerman,C Decastro,J Moore,NJ Chao,

For similar surgical procedures, operative: transplantation: transplantation, homologous research abstracts see: surgical procedures, operative: transplantation: transplantation, homologous research

PUBMED ID PMID:

MEDLINE DATE:

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of clinical oncology : official journal of

VOLUME: 25

Page Numbers: 690-7

Journal Abbreviation: J. Clin. Oncol.

ISSN: 1527-7755

DAY: 16

MONTH: 01

YEAR: 2007

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Keywords Mesh Terms:

KEYWORDS: Transplantation, Homologous

MESH TERMS: methods

Chemical & Substance for Abstract: Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Information

Substance Name: Myeloablative Agonists

Registry Number: 0

Grant and Affiliation Information for Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

AFFILIATION: Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA. rizzi003@mc.duke.edu

Country: United States

AGENCY: United States NCRR

GRANT: 5K23RR16063-01

ACRONYM: RR

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution Related Publications

• 3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.
• Acupuncture treatment for 68 cases of functional impairment induced by cerebral hemorrhage at the convalescence stage.
• Cellular homeoproteins, SATB1 and CDP, bind to the unique region between the human cytomegalovirus UL127 and major immediate-early genes.
• Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling.
• Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
• Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
• Functional imaging for early prediction of response to chemoradiotherapy: 3'-deoxy-3'-18F-fluorothymidine positron emission tomography--a clinical application model of esophageal cancer.
• Functional origins of fitness effect-sizes of compensatory mutations in the DNA bacteriophage phiX174.
• Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse.
• Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity.
• Neurotrophins, synaptic plasticity and dementia.
• Numerical equivalence of imputing scores and weighted estimators in regression analysis with missing covariates.
• P43.04: The mean gray value of VOCAL technique can assist in making differential diagnosis of chocolate cyst and other benign ovarian tumor: a preliminary study.
• P48.03: Integration of imaging studies and endoscopic management of purulent vaginal discharge: undiagnosed vaginal ectopic ureter associated with ipsilateral dysplastic pelvic kidney and bicornuate uterus.
• Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
• Positioning a safe gastric puncture point before percutaneous endoscopic gastrostomy.
• Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport.
• Structured correlation in models for clustered data.
• The relationship between quality of life and posttraumatic stress disorder or major depression for firefighters in Kaohsiung, Taiwan.
• The tyrosine kinase Fyn determines the localization of TrkB receptors in lipid rafts.
• Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction.
• Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation.
• Transplantation of vascular endothelial cells mediates the hematopoietic recovery and survival of lethally irradiated mice.
• [Attenuation of chronic stress-induced hippocampal damages following physical exercise]
• [Carotid angioplasty and stenting in patients with high-risk carotid stenosis]
• [Effect of two different ring liner thickness on the precision of castings]
• [Stent-assisted percutaneous transluminal angioplasty for intracranial vertebral artery stenosis: a reports of two cases]
• [Study on different thickness and chromatics of various opaques]
• [Study on the surface roughness of three dental alloys soaked in artificial saliva]
• [The study on color space of the VINTAGE & UNIBOND standard color]